DRUGS FOR SYMPTOMATIC TREATMENT OF HUNTINGTON'S DISEASE: A NEURODEGENERATIVE DISORDER
Journal Title: Journal of Biomedical and Pharmaceutical Research - Year 2013, Vol 2, Issue 6
Abstract
Huntington’s disease is a devastating inherited neurodegenerative disease characterized by progressive motor, cognitive, and psychiatric symptoms. Patients may present with any of these symptoms, and familiarity with the phenotype is therefore important. Chorea and loss of balance are early symptoms that patients notice, although families often notice cognitive or personality changes before this. Although no therapy is currently available to delay the onset of symptoms or prevent the progression of the disease, symptomatic treatment of patients with Huntington disease (HD) may improve the quality of life and prevent complications. As is the case with other neurological diseases, HD makes individuals more vulnerable to side effects from medications, particularly cognitive adverse effects. Symptomatic treatment for HD can be divided into drugs to treat the movement disorder and drugs to treat psychiatric or behavioral problems. Symptomatic treatment of Huntington’s disease involves use of Dopamine antagonists, presynaptic dopamine depleters, Antidepressants, Tranquillizers, Anxiolytic Benzodiazepines, Anticonvulsants and Antibiotics. Several medications including baclofen, idebenone and vitamin E have studied in clinical trials with limited samples. This article reviews current therapeutic agents for treatment of the symptoms of Huntington’s disease. The aim of present article is to provide in depth knowledge about symptomatic treatment and other therapies involved in the management of Huntington’s disease.
Authors and Affiliations
Pranab Prakash Panigrahi*| Executive, QC (Stability), Aurobindo Pharma Ltd., Mahaboob Nagar, Andhra Pradesh, India-509302
Keywords
Related Articles
- EP ID EP2352
- DOI -
- Views 342
- Downloads 22
Recent Advances in Novel Semisolid Dosage Forms: An Overview
Semisolids constitute a significant proportion of pharmaceutical dosage forms. They serve as carriers for drugs that are topically delivered by way of the skin, cornea, rectal tissue, nasal mucosa, vagina, buccal tissue,...
CYTOPROTECTIVE EFFICACY OF DRDE-07 AND DRDE-30 AGAINST CISPLATIN INDUCED NEPHROTOXICITY
Aim: The objective of the study was to investigate the cytoprotective action of DRDE-07 and DRDE-30 against cisplatin induced nephrotoxicity in mice. Subjects and Methods: Randomly bred Swiss female mice (25-30 g) were s...
AN OVERVIEW ON LAGENARIA SICERARIA (BOTTLE GOURD)
Cucurbitaceae family is a major source of medicinal agents’ science ancient times. Various plants parts including fruits of this family have been established for their pharmacological effect. Lagenaria siceraria (Molina)...
CURRENT NECESSITY OF PROTEASES: OVERVIEW
The use of proteases as medicine is also popular as the study of proteases has helped us better understands inflammatory conditions and immune regulation. If a protein (part of living cell) component including other nece...
Method Development and Validation of Montelukast in Bulk and Pharmaceutical Dosage form by RP-HPLC
The present work describes a simple, precise and accurate HPLC method for estimation of montelukast sodium in bulk and in tablet dosage form. Montelukast sodium is a selective and orally active leukotriene receptor antag...